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Abstract 
BACKGROUND: Postoperative nausea and vomiting (PONV) is a common complaint after strabismus surgery 
that leads to unpleasantness, increased hospitalisation time and increased costs. In severe cases, it can lead to 
dehydration, electrolyte disturbances, aspiration, pneumonia, and even sutures opening.  
AIM: This study was conducted to compare the effects of both ondansetron and granisetron on the reduction of 
PONV after strabismus surgery. 
METHODS: This randomised, and the double-blind clinical study was conducted on patients with ASA I and II 
undergoing strabismus surgery with age over 3 years old in Shafa Hospital, Kerman University of Medical 
Sciences during 2017 under general anaesthesia. Patients with inclusion criteria were randomly assigned to one 
of three groups including Ondansetron (A), Granisetron (B) and control group (C). Matching cases and controls on 
drugs were fully completed. Furthermore, 100 μg/kg of Ondansetron was intravenously injected, followed by 
injection of 40 μg/kg Granisetron for another intervention group. All patients underwent the same anaesthetic 
procedure and intravenous injection of drugs during anaesthesia induction. The severity of nausea and vomiting in 
recovery, 6 and 18 hours after the operation were verified according to the Verbal Rating Scale (VRS). Our data 
were analysed by Chi-square, ANOVA and TUKEY tests via SPSS version 18. 
RESULTS: There was no significant difference between the three groups in terms of age and sex. The incidence 
of postoperative nausea in recovery among three groups of A, B and C was determined to be 15, 7.5 and 37.5%, 
respectively. No significant difference was found between the two groups A and B (P = 0.68), although there was 
a significant difference between these two groups and group C (P < 0.05). The incidence of nausea at 6 hours 
after surgery in groups A, B and C was recorded as 40, 15 and 65% respectively, indicating that the incidence of 
nausea in group B was significantly lower than the other two groups, while showed a significant difference with 
group A (P = 0.039) and group C (P < 0.05). Also, the incident of nausea between groups was not statistically 
significant 18 hours after surgery (P < 0.05). Additionally, no significant difference was found in different groups in 
terms of vomiting incidence in recovery, 6 and 18 hours after surgery (P < 0.05).  
CONCLUSION: Our study suggests that Granisetron is more effective in preventing PONV during 6 hours after 
the surgery in comparison with Ondansetron which makes it a favourable alternative for preventing PONV. 
 
 
 
 
Introduction 
 
Postoperative nausea and vomiting (PONV) 
are the second most adverse and complicated event 
following surgery [1], [2]. This usually occurs in the 
post-anaesthetic phase and ends within 24 hours, 
which its incidence ranged from 30 to 20% [3]. Risk 
factors for postoperative nausea and vomiting include 
females, duration of anaesthesia for more than half an 
hour, age above 3 years, type of surgery, personal or 
familial history of postoperative nausea and vomiting, 
or motion sickness [4], [5]. 
The type of surgery is not necessarily the 
most important cause of PONV. The occurrence of 
PONV following various surgeries is more due to the 
factors related to the patient and anaesthesia than the 
self-surgery issue [6], [7]. PONV is an unpleasant 
experience that patients often find worse than 
postoperative pain [7]. Prevention of PONV in patients 
at high risk of this complication improves 
postoperative satisfaction [8]. Although PONV is self-
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
3196                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
limiting, its occurrence following surgery can lead to 
multiple complications such as aspiration of stomach 
contents, suture opening, oesophagal rupture, 
subcutaneous emphysema and pneumothorax [9], 
[10]. PONV delayed the patient's recovery and 
prolonged unexpected hospitalisation after an 
outpatient operation [11]. PONV prolongs the 
discharge time to 61-47 minutes. The annual impact 
of PONV on healthcare costs is estimated to be 
several hundred million dollars in the United States 
[12]. The reason for the lack of definitive prevention of 
PONV is the presence of multiple factors associated 
with this disorder, so the main solution to prevent this 
complication is still the use of anti-nausea drugs in 
clinical cases. Ondansetron is a serotonin receptor 
antagonist that is considered as the most effective 
anti-vomiting drug for preventing PONV [13], [14]. 
Granisetron is a serotonin 5-HT₃ receptor antagonist, 
with a half-life of about two times that of Ondansetron 
[13], [14]. 
Strabismus surgery is among the operations 
with a high prevalence of PONV (75-40%), which 
causes long recovery, high costs, increased bleeding, 
increased eye pressure and patient dissatisfaction 
due to the nature of the strabismus surgery caused by 
the muscle tightening [15]. Therefore, we compared 
the effect of two Ondansetron and Granisetron drugs 
on nausea and vomiting following strabismus surgery. 
 
 
Material and methods 
 
This randomised, and the double-blind clinical 
study was conducted on patients undergoing 
strabismus surgery with age over 3 years old in Shafa 
Hospital, Kerman University of Medical Sciences 
during 2017. Sampling was done based on purpose 
and field information was collected using a 
questionnaire. 
Considering the maximum sample size, the 
standard deviation in similar studies, alpha coefficient 
of 5% and power of 80% [16], [17], 120 patients with 
strabismus surgery were randomly assigned to 3 
groups of 40 subjects in the placebo, Ondansetron 
and Granisetron. 
Alpha = 0.05 (two-sided)  Z (1-α/2) 1.959964 
power = 0.8   Z (1-β) 0.841621 
m1 = 2   D 1 
m2 = 3   s
2
 1.69 
sd1 = 1.2   sd1
2
 1.44 
sd2 = 1.4   sd2
2
 1.96 
        
     n1 26.68619 
     n2 26.68619 
 
 
Inclusion criteria: 1) Patients undergoing 
strabismus surgery over the age of 3 years 
And 2) Class 1 & 2 American Society of 
Anaesthesiologists' (ASA) classification of Physical 
Health. Exclusion criteria: 1) History of previous 
surgery and anaesthesia with postoperative nausea 
and vomiting; 2) History of Ménière's disease, motion 
sickness or migraine; 3) Dissatisfaction with surgery; 
4) Use of drugs that affect nausea and vomiting within 
24 hours of surgery; 5) Pregnancy or breastfeeding. 
Patients with inclusion criteria were randomly 
assigned to one of three groups, including 
Ondansetron, Granisetron and placebo (normal saline 
administration). In a randomised clinical trial was 
blinded, in which neither the patient nor the evaluating 
person informed the type of drug used. Furthermore, 
matching cases and controls on drugs were fully 
completed. 
Induction of all three groups was performed 
with midazolam 1 mg, fentanyl 100-50 micrograms, 
thiopental 5 mg/kg and atracurium 0.2 mg/kg. 
Maintenance of anaesthesia was carried out in all 
three groups with propofol infusion (100 μg/kg/min) 
and 50% N2O-O2 mixture. 
After giving premed to the patient, 100 μg/kg 
of Ondansetron was intravenously injected, followed 
by injection of 40 μg/kg Granisetron for another 
intervention group. 
All recovery personnel and section were 
unaware of the patient groups and the type of drug 
used. The severity of nausea and vomiting were 
evaluated by an anesthesiologist at the recovery and 
after transferring to the section during 6 hours 
following the operation and then after discharge from 
the hospital during the next 18 hours. A drug for the 
treatment of nausea and vomiting was not given to 
patients during anaesthesia. In case of severe nausea 
and vomiting, a dose of dimenhydrinate (mg) was 
administered to the patient. Additionally, patients who 
suffered from nausea and vomiting in recovery, 
received metoclopramide 0.1 mg/kg. 
Because the two drugs used are both anti-
nausea and -vomiting, and only their effect and 
potency are different, no additional drugs have been 
given to patients in recovery. Recording the age, 
height, weight and duration of anaesthesia, the 
severity of nausea and vomiting in recovery were 
done by anaesthesia technician. After transferring the 
patient to the section, the patients were evaluated by 
the anaesthesia resident within 6 hours after the 
operation and then after discharge from the hospital 
within the next 18 hours. The severity of nausea is 
measured according to the Verbal Rating Scale 
(VRS). By this method, an individual without nausea is 
assigned zero, in case of less than two nausea 
episode, mild nausea was considered, as followed 
twice or more (moderate nausea). The incidence of 
vomiting is considered to be the same as severe 
nausea. 
Ethical considerations included: 1. Approval of 
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the plan by the Research Council of the School of 
Medicine; 2. Informed consent was obtained from the 
patient to participate in the study, of mention, obtained 
by the legal parents for the children; and 3. Both anti-
nausea drugs are used routinely without any 
complications if any unwanted side effects were 
observed, each treatment was followed by a 
withdrawal from the study, but no complication was 
observed.  
 
Data analysis 
Information for each group was coded as 1, 2 
and 3, and the recorded in the checklist for each drug 
or placebo, followed by statistical analysis through the 
SPSS version 18 software. Data analysis 
Information for each of the 3 groups, coded 1, 2 and 
3, was recorded in the checklist for each drug or 
placebo, and then entered the SPSS version 18 
software. Using the Kolmogorov-Smirnov test, the 
data were analysed for normal distribution. Depending 
on the distribution of data and quantitative or 
qualitative values, quantitative data such as age were 
analysed using one-way ANOVA test regarding their 
normalisation, while Non-parametric Kruskal-Wallis H 
test was used for data with skewed distribution. If 
parametric or parametric tests showed significant 
values, Dunn's multiple comparisons test and Tukey 
tests were employed to compare the groups. Chi-
square test was applied to evaluate the qualitative 
variables. Regarding the lack of time assessment, 
repeated tests such as repeated measures ANOVA 
were not used. In all tests, a significant level of 0.05 
was considered. 
 
 
Results 
 
Our study was conducted on 120 patients 
who referred to the operating room of the hospital for 
strabismus surgery and randomly divided into three 
groups: A (Ondansetron), B (Granisetron) and C 
(Placebo). Study population consisted of 76 male 
patients (63.3%) and 44 (36.7%) female. Among 
them, 26 patients received A, 21 drug B and 29 C, 
respectively. Among the female patients, 14 received 
A, 19 B and 11 C, respectively. Forty people were 
considered for each group A, B and C, without 
regarding gender. 
The results of the chi-square test showed no 
significant relationship between nausea rate in all 
three groups and sex (P = 0.175). The mean age and 
standard deviation in each of groups A, B, C were 
determined as 43.68 ± 19.3, 22.78 ± 16.1 and 97.74 ± 
13.1. 
The mean age of patients in Ondansetron, 
Granisetron and control groups was 19.43, 16.22 and 
13.97, respectively. The mean age of the subjects 
was 16.49 years. Based on the ANOVA test, no 
significant difference was found between the groups in 
terms of age (P = 0.332). 
Table 1 shows the magnitude and severity of 
nausea and vomiting in recovery. Of the 120 
participants, 15% had a feeling of nausea in group A, 
followed by group B (7.5%) and group C (37.5%). The 
best possible status for lack of nausea episode was in 
group B with 92.5%, followed by group A (85%) and 
group C (62.5%). The highest vomiting (3 cases) was 
recorded in group C, followed by group A (one 
person) and group B (none), (Table 1). 
Table 1: The rate and severity of nausea and vomiting in 
recovery among three groups (A, B, C) 
Variable  
An (Endonestrone) B (Granisetron) C (control) Total 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
Recovery 
No nausea 43 58 43 92.5 58 62.5 69 58 
Mild nausea 3 08 4 7.5 3 17.5 03 11.7 
Moderate 
nausea 
0 2.5 8 8 8 12.5 9 8 
Severity 
Nausea 
(Vomit) 
0 2.5 8 8 4 7.5 3 3.3 
 
Table 2 indicates the measurement of nausea 
episodes and severity in 6 hours after surgery. Of the 
120 patients, 60% of the subjects did not feel 
nauseous, while 23.3% had mild nausea, followed by 
moderate nausea (7.5%) and severe nausea 
(vomiting: 9.2%).  
The most common nausea episodes were 
observed in group C (placebo) with 65%, while 
episodes were 40% in group A and 15% in group B. In 
other words, the best possible situation was seen in 
Group B (85% without nausea). Vomiting in groups A, 
B and C was 7.5, 2.5 and 17.5%, with the lowest 
vomiting in group B and the highest in group C (Table 
2). 
Table 2: The rate and severity of nausea and vomiting in the 
first 6 hours after surgery in the three groups (A, B, C) 
Variable  
An (Endonestrone) B (Granisetron) C (control) Total 
Freque
ncy 
Percent Frequen
cy 
Percent Freque
ncy 
Percent Frequen
cy 
Percent 
6h after 
No nausea 53 98 43 58 03 48 35 98 
Mild nausea 08 58 3 08 03 48 55 23.3 
Moderate 
nausea 
4 7.5 0 2.5 8 12.5 6 7.5 
Severity 
Nausea 
(Vomit) 
4 7.5 0 2.5 3 17.5 00 9.2 
 
The incidence rate and severity of nausea 
and vomiting in 18 hours after surgery are listed in 
Table 2. After 18 hours of operation, 96.7% of the 
patients had no nausea episode One in group A, one 
in group B and two in group C patients, expressed the 
feeling, while vomiting was seen only in the group C 
(Table 3). 
Table 3: Incidence and severity of nausea and vomiting 18 
hours after operation in three groups (A, B, C) 
Variable  
An (Endonestrone) B (Granisetron) C (control) Total 
Frequen
cy 
Percent Frequen
cy 
Percent Freque
ncy 
Percent Freque
ncy 
Percent 
05 h 
after 
No nausea 46 97.5 46 97.5 45 68 009 96.7 
Mild nausea 0 2.5 0 2.5 0 2.5 4 2.5 
Moderate nausea 8 8 8 8 8 8 8 8 
Severity Nausea 
(Vomit) 
8 8 8 8 0 2.5 0 0.8 
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The incidence of postoperative nausea in 
recovery in the three groups of Ondansetron, 
Granisetron and control was determined to be 15, 7.5 
and 37.5%, respectively (Table 4). The result of the 
test demonstrated a significant general relationship 
between the groups. Based on the results of Tukey 
test, we found that despite the low nausea rate in the 
Granisetron group compared to the Ondansetron 
group, no significant difference was found between 
the two groups in terms of nausea (P = 0.658), 
although there was a significant difference between 
the two groups and the control group (P < 0.05) (Table 
4). 
Table 4: Comparison of the three groups in terms of 
postoperative nausea in recovery 
Variable 
An (Endonestrone) B (Granisetron) C (control) Total Results of 
the Chi-
Square 
Test 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
Recovery Nausea 9 08 4 7.5 08 37.5 53 58 0.002 
 
Regarding the incidence of vomiting in 
recovery, although it was relatively reduced in the 
Granisetron group in comparison with Ondansetron 
and placebo, but no statistically significant difference 
was observed between the groups (P = 0.164) (Table 
5). 
Table 5: Comparison of the three groups in terms of 
postoperative vomiting in recovery 
Variable  An (Endonestrone) B (Granisetron) C (control) Total Results of 
the Chi-
Square 
Test 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
Recovery Vomiting 0 2.5 8 8 4 7.5 3 3.3 0.164 
 
The incidence of nausea in the 6 hours after 
strabismus surgery in the Ondansetron, Granisetron 
and control groups was 40, 15 and 65% respectively, 
indicating that the incidence of nausea was 
significantly lower in the Granisetron group when 
compared with the other two groups.  
Table 6: Comparison of the three groups in terms of 
postoperative nausea in 6 hours after surgery 
Variable  
An (Endonestrone) B (Granisetron) C (control) Total Results of the 
Chi-Square 
Test 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
9H 
after 
Nausea 09 38 9 08 59 98 35 38 0.0001 
 
Although the incidence of vomiting 
demonstrated a decreasing trend in the granitic group 
at 6 hours after the operation as compared to placebo 
and indomethacin, there was no statistically significant 
difference between the groups (P = 0.061; Table 6 
and 7). 
Table 7: Comparison of the three groups in terms of vomiting 
in 6 hours after surgery 
Variable  
An (Endonestrone) B (Granisetron) C (control) Total Results 
of the 
Chi-
Square 
Test 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
9 h 
after 
Vomiting 4 7.5 0 2.5 3 17.5 00 9.2 0.061 
 
The incidence of nausea was not significantly 
different between the groups 18 hours after surgery (P 
= 0.772).  
Table 8: Comparison of the three groups in terms of nausea 18 
hours after surgery 
Variable  
An (Endonestrone) B (Granisetron) C (control) Total Results 
of the 
Chi-
Square 
Test 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
05 h 
after 
Nausea 0 2.5 0 2.5 5 8 3 3.3 0.772 
Also, there was no significant difference 
between the groups in terms of vomiting incidence 18 
hours after the operation (P = 0.336; P < 0.05; Table 8 
and 9). 
Table 9: Comparison of the three groups in terms of vomiting 
18 hours after surgery 
Variable  
An (Endonestrone) B (Granisetron) C (control) Total Results 
of the 
Chi-
Square 
Test 
Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
18 h 
after 
Vomiting 0 0 0 0 1 0.52 0 0.8 0.365 
 
 
 
Discussion 
 
Today, the increasing number of surgeries 
has increased the desire for early release of patients 
from recovery. Decreasing the incidence of PONV has 
accelerated the discharge of patients, reduces the 
length of hospitalisation or re-admission, and leads to 
patient satisfaction [18], [19]. In this regard, we aimed 
to compare the effect of both Ondansetron, and 
Granisetron on nausea and vomiting following 
strabismus surgery. 
The findings of the statistical tests showed 
that there was no significant difference between the 
level of nausea in all three groups and gender (p = 
0.175). Furthermore, the mean age of patients in the 
three groups revealed no significant difference 
between the groups in terms of age (P = 0.332). The 
best possible status for lack of nausea was observed 
in group B (92.5%), followed by group A (85%) and 
group C (62.5%). Despite the low nausea rate in the 
Granisetron group in comparison with Ondansetron, 
there was no significant difference between them (P = 
0.658); 
The highest vomiting (3 cases) was recorded 
in group C, followed by group A (one person) and 
group B (none), (Table 1). However, there was a 
significant difference between the two intervention 
groups and the control group (P < 0.05). 
The highest vomiting (3 cases) was recorded 
in group C, followed by group A (one person) and 
group B (none). Although recovery vomiting was 
relatively reduced in the Granisetron group as 
compared to Ondansetron and placebo, but no 
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statistically significant difference was found between 
the groups (P = 0.164). 
Based on the results presented herein, 60% 
of the subjects did not feel nauseous, while 23.3% 
had mild nausea, followed by moderate nausea 
(7.5%) and severe nausea (vomiting: 9.2%).  
The most common nausea episode was 
observed in group C (placebo) with 65%, while the 
episode was 40% in group A and 15% in group B. The 
best possible situation was seen in Group B (85% 
without nausea); Statistically, the incidence of nausea 
in the Granisetron group was significantly less than 
the other two groups, and this difference was 
significant in comparison with the Ondansetron group 
(P = 0.039) and the control group (P < 0.05). 
In addition, vomiting in groups A, B and C was 
determined as 7.5, 2.5 and 17.5%, where the lowest 
vomiting was observed in group B and the highest in 
group C. Although, relative reduction of vomiting was 
observed in the Granisetron group as compared to 
placebo and Ondansetron, but no statistically 
significant difference was found between the groups 
(P = 0.061). 
The incidence rate and severity of nausea 
and vomiting in 18 hours after surgery are listed in 
Table 2. After 18 hours of operation, 96.7% of the 
patients had no nausea episode. One in group A, one 
in group B and two in group C expressed episodes 
while vomiting was seen only in the group C. 
The incidence of nausea was not statistically 
significant among the groups 18 hours after surgery 
(P = 0.772). Moreover, there was no significant 
difference between the groups in terms of vomiting18 
hours after surgery (P = 0.365), (P < 0.05). 
 Very limited studies have been conducted on 
the effects of both Granisetron and Ondansetron on 
reducing the incidence of PONV in strabismus 
surgery, although more studies are available for other 
surgeries such as laparoscopy. Most studies have 
shown that Granisetron is more effective than 
Ondansetron which is consistent with our study, 
although some studies have also shown contradictory 
results.  
A study assessed the effect of Granisetron, 
Ondansetron, Midazolam combination with 
Dexamethasone for reduction of PONV after 
strabismus surgery among 100 children ASA class I 
and II, where findings did not show significant 
differences between different groups [20]. 
Another study evaluated antiemetic effects of 
Ondansetron and Granisetron in preventing 
postoperative nausea and vomiting in subjects 
undergoing daycare laparoscopic tubal ligation where 
minimal emetic episodes in patients receiving 
intravenous granisetron when comparing with those 
receiving ondansetron and placebo. The study 
mentioned above indicated that emetic episodes were 
attributed to 7% of patients receiving intravenous 
granisetron, followed by 20% in the ondansetron 
group and 50% in placebo group C [21]. 
In a randomized double-blind investigation, 
100 female patients were assessed for effect of 
Ondansetron and Granisetron in preventing PONV 
(intervals of 6-0, 12-6, 18-12 and 24-18 after surgery) 
in subjects undergoing elective laparoscopic 
cholecystectomy, where a significant was found in the 
incidence of PONV among two groups after 6 hours to 
24 hours [16]. 
Gauchan et al. evaluated the antiemetic 
efficacy of Ondansetron and Granisetron in patients 
undergoing laparoscopic cholecystectomy during the 
first 24 hours after anaesthesia. They indicated that 
Granisetron was effectively capable of increasing 
incidence of PONV as compared to Ondansetron in 
the first 24 hours [17]. 
In another study by Savant et al., the effects 
of ondansetron (4 mg, 2 mL) and granisetron (2 mg, 2 
mL) was assessed in preventing PONV in subjects 
undergoing oral and maxillofacial surgery. 
Except for the headache side effect, it has 
been shown that the incidence of nausea and 
vomiting in the Granisetron group was significantly 
lower than that of Ondansetron [22]. 
In conclusion, our study suggests that 
Granisetron is more effective in preventing PONV for 
6 hours after the surgery in comparison with 
Ondansetron which makes it a favourable alternative. 
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